(Q44019385)

English

Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study

scientific article published on 17 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kai Jie Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Wan Yi Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Xia Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Yi Ming Jia

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Gui Qin Peng

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Li Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

17 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

European Journal of Drug Metabolism and Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

25-31

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Anaemia after enalapril in a child with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process.

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Clinical pharmacokinetics of paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in chinese healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon

1 reference

https://api.crossref.org/works/10.1007%2FS13318-013-0136-Y

21 January 2018

Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double‐blind, randomized, placebo‐controlled phase I/II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-administration of cyclosporin enables oral therapy with paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Taxol metabolism and disposition in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of antihepatotoxic activity of glycyrrhizin. I: Effect on free radical generation and lipid peroxidation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic metabolism and biliary excretion of Taxol in rats and humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cremophor EL, solvent for paclitaxel, and toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/23681836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13318-013-0136-Y

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44019385&oldid=2206391405"